Organetix, Inc. (OTC BB: OGTX), a developer of nutraceuticals and bioceuticals initially targeting Hepatitis C, Cirrhosis, other diseases of the human liver, and alleviating symptoms of patients undergoing chemotherapy, announced today that it will initiate testing a nutraceutical anti-viral formula on the Avian Influenza (Bird Flu) and the Avian Influenza (H5N1) virus.
